TB Drug Accelerator Program
Aiming to speed up the discovery and development of novel compounds against tuberculosis (TB)....
AbbVie, AstraZeneca, Bayer AG, Eisai, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, MSD
GLOBAL HEALTH
PROGRESS
How the innovative biopharmaceutical industry and our partners are achieving the Sustainable Development Goals (SDGs)
Explore our collaborations
Global Health Progress is an interactive resource hub highlighting collaborations between the innovative biopharmaceutical industry and our partners to support the SDGs
OUR MEMBERS & PARTNERS
Over 35 IFPMA members are working with partners from academia, development organizations, NGOs, foundations and other business sectors.
Learn More
OUR COLLABORATIONS
With over 250 collaborations, Global Health Progress details the scope, scale, and breadth of our collaborations working to strengthen health systems and expand access to quality healthcare.
Learn More
OUR APPROACH
Founded on patients need, we are strengthening health systems by developing and producing medicines to meet these needs and increasing the availability, accessibility and affordability of health services.
Learn More
COLLABORATION IS AT THE HEART OF THE SDGs
The private sector has a key role to play in addressing the global challenges we face in health, wellbeing and prosperity. Our efforts help to address these challenges and support SDGs.
Learn more about the SDGsFROM SUPPORTING PEOPLE LIVING WITH DIABETES IN VIETNAM TO TARGETING MALARIA IN THE CONGO…
Explore the full depth and diversity of our collaborations
The London Declaration on NTDs
On 30 January 2012, pharmaceutical companies, donors, endemic countries and non-government organisations came...
AbbVie, Bayer AG, Bristol Myers Squibb, Eisai, GlaxoSmithKline, Johnson & Johnson, Merck, MSD, Novartis, Pfizer Inc, Sanofi
Access Accelerated Initiative
Tackling the growing burden of non-communicable diseases in low and middle-income countries and supporting...
Access Accelerated, Almirall, Astellas Pharma Inc, Bayer AG, Bristol Myers Squibb, Celgene, Chiesi Farmaceutici, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Eli Lilly and Company, F. Hoffmann – La Roche Ltd., International Federation of Pharmaceutical Manufacturers & Associations, Johnson & Johnson, Menarini Group, Merck, MSD, Novartis, Pfizer Inc, Sanofi, Servier, Shionogi & Co., Ltd., Sumitomo Pharma, Takeda Pharmaceutical Company Limited, UCB
directory of collaborations
REPORTING ON PROGRESS,
CALLING FOR CONTINUED COLLABORATIVE ACTION
Over the past decade strong progress has been made on a number of diseases but there is still much to be done to step up the fight and ensure universal health for all.
CATALYSING GLOBAL ACTION ON NCDs
Access Accelerated unites more than 20 innovative biopharmaceutical companies and partners to tackle the non-communicable diseases (NCDs) burden in low- and middle-income countries (LMICs). Access Accelerated has developed the Access Accelerated Open Platform, a first of-its-kind resource to share knowledge and catalyze action around advancing NCD prevention, treatment and care.
Explore the Access Accelerated Open Platform
CHARTING DECADES OF ADVANCES IN GLOBAL HEALTH PROGRESS
50 Years of Global Health Progress traces global health progress over the half century and the pioneering collaborative role the innovative biopharmaceutical industry has played not only to deliver prevention and treatment, but to strengthen health systems around the world.